News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Business
Artimplant Interim Report January – September 2010
October 28, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
VÄSTRA FRÖLUNDA, Sweden--(BUSINESS WIRE)--Regulatory News: Artimplant AB (STO:ARTIB):
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
MORE ON THIS TOPIC
Layoffs
Editas Axes 60% of Staff, Sickle Cell Therapy After Failing to Find Partner
December 13, 2024
·
2 min read
·
Tristan Manalac
Regulatory
Novo Nordisk Snags Kidney Disease Expansion for Ozempic in Europe
December 12, 2024
·
1 min read
·
Kate Goodwin
Layoff Tracker
Bavarian, BenevolentAI, Chroma Medicine and Nvelop Therapeutics Cut Staff
December 12, 2024
·
205 min read
·
BioSpace Editorial Staff
Breast cancer
BioNTech Builds Case for PD-L1/VEGF Bispecific With Promising Breast Cancer Data
December 11, 2024
·
2 min read
·
Tristan Manalac
